B.Braun LogoB.Braun Logo
      • Strona główna
      • Leki dożylne
      • Leki przeciwwymiotne
      • Ondansetron B. Braun 0.08/0.16 mg/ml solution for infusion

      Ondansetron B. Braun0,16 mg/ml-Antiemetic for intravenous infusion
      Ondansetron B. Braun 0.08/0.16 mg/ml-Antiemetic for intravenous infusion
      Ondansetron 8mg/50ml-Antiemetic for intravenous infusion
      Ondansetron B. Braun0,16 mg/ml-Antiemetic for intravenous infusion
      Ondansetron B. Braun0,16 mg/ml-Antiemetic for intravenous infusion
      Ondansetron B. Braun 0.08/0.16 mg/ml-Antiemetic for intravenous infusion
      Ondansetron 8mg/50ml-Antiemetic for intravenous infusion

      Ondansetron B. Braun 0.08/0.16 mg/ml solution for infusion
      Antiemetic for intravenous infusion

      Adults

      • Prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy (CINV/RINV)
      • Prevention and treatment of post-operative nausea and vomiting (PONV).

      Paediatric population

      • Management of chemotherapy-induced nausea and vomiting (CINV) in children aged ≥ 6 months
      • Prevention and treatment of postoperative nausea and vomiting (PONV) in children aged ≥ 1 month.

      Available in:

      • Ondansetron 0.08 mg/ml: Ecoflac® plus 100 ml
      • Ondansetron 0.16 mg/ml: Ecoflac® plus 50 ml

      Advantages:

      • MHRA advice for healthcare professionals to dilute Ondansetron and infuse over at least 15 minutes for patients age 65 years or older.
      • Ready-to-use dose product eliminates intermediate steps and helps to prevent dosage errors.
      Czytaj więcej